2.83

4.04% 0.11

After Hours: 2.81 -0.02 -0.71%

Rocket Pharmaceuticals Inc (RCKT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Rocket Pharmaceuticals Inc stock is traded at $2.83, with a volume of 4.49M. It is up +4.04% in the last 24 hours and down -56.46% over the past month. Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Previous Close:

$2.72

Open:

$2.72

24h Volume:

4.49M

Relative Volume:

0.95

Market Cap:

$340.45M

Revenue:

Net Income/Loss:

$-258.08M

P/E Ratio:

-1.0291

EPS:

-2.75

Net Cash Flow:

$-202.32M

1W Performance:

-6.60%

1M Performance:

-56.46%

6M Performance:

-75.89%

1Y Performance:

-86.32%

1-Day Range:

$2.66

$2.95

1-Week Range:

$2.66

$3.19

52-Week Range:

$2.19

$26.98

Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile

Name

Rocket Pharmaceuticals Inc

Sector

Healthcare (1172)

Industry

Biotechnology (661)

Phone

646-440-9100

Address

350 FIFTH AVENUE, NEW YORK, NY

Employee

299

Twitter

@rocketpharma

Next Earnings Date

2024-11-04

Latest SEC Filings

RCKT's Discussions on Twitter

Compare RCKT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCKT Rocket Pharmaceuticals Inc	2.83	340.45M	0	-258.08M	-202.32M	-2.75
VRTX Vertex Pharmaceuticals Inc	448.40	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	513.58	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	312.32	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	537.92	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	252.78	28.51B	3.81B	-644.79M	-669.77M	-6.24

Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-30-25	Downgrade	Evercore ISI	Outperform → In-line
May-28-25	Downgrade	Goldman	Neutral → Sell
May-28-25	Downgrade	JP Morgan	Overweight → Neutral
May-28-25	Downgrade	Jefferies	Buy → Hold
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform
May-28-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
May-27-25	Downgrade	Needham	Buy → Hold
May-27-25	Downgrade	TD Cowen	Buy → Hold
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Dec-30-24	Initiated	Wedbush	Outperform
Dec-18-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Apr-02-24	Initiated	Goldman	Neutral
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Feb-01-23	Initiated	Morgan Stanley	Overweight
Nov-08-22	Initiated	Canaccord Genuity	Buy
Nov-01-22	Initiated	BTIG Research	Buy
Jul-08-22	Initiated	Raymond James	Outperform
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy
Feb-18-21	Initiated	Needham	Buy
Dec-16-20	Initiated	UBS	Buy
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy
Feb-05-19	Initiated	Oppenheimer	Outperform
Sep-13-18	Initiated	Ladenburg Thalmann	Buy
Jul-10-18	Initiated	William Blair	Outperform

View All

Rocket Pharmaceuticals Inc Stock (RCKT) Latest News

11:30 AM

RCKT INVESTOR NOTICE: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit – Company AnnouncementFT.com - Financial Times

11:30 AM

11:18 AM

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - FinancialContent

11:18 AM

02:35 AM

Rocket Pharmaceuticals (NASDAQ:RCKT) Price Target Lowered to $5.00 at UBS Group - Defense World

02:35 AM

Jun 17, 2025

RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit - PR Newswire

Jun 17, 2025

Rocket Pharmaceuticals (RCKT) Price Target Lowered by Analyst | - GuruFocus

Jun 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc.RCKT - PR Newswire

Jun 17, 2025

UBS Cuts Price Target on Rocket Pharmaceuticals to $5 From $12, Maintains Buy Rating - marketscreener.com

Jun 17, 2025

UBS Adjusts Price Target for Rocket Pharmaceuticals (RCKT) Amid Program Developments | RCKT Stock News - GuruFocus

Jun 17, 2025

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. LawsuitRCKT - PR Newswire

Jun 17, 2025

Jun 16, 2025

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vestis, PepGen, Tempus, and Rocket and Encourages Investors to Contact the Firm - GlobeNewswire Inc.

Jun 16, 2025

RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ... - Bluefield Daily Telegraph

Jun 16, 2025

Rocket Pharmaceuticals, Inc. Sued for Securities Law - GlobeNewswire

Jun 16, 2025

Investors in Rocket Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before August 11, 2025 to Discuss Your RightsRCKT - GuruFocus

Jun 16, 2025

Jun 15, 2025

Levi & Korsinsky Urges Rocket Pharmaceuticals, Inc. (RCKT) Shareholders to Act Before Lead Plaintiff Deadline August 11, 2025 - ACCESS Newswire

Jun 15, 2025

Recover Investment Losses: Levi & Korsinsky Files Class Action Against Rocket Pharmaceuticals, Inc. (RCKT) - ACCESS Newswire

Jun 15, 2025

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals - marketscreener.com

Jun 15, 2025

RCKT STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 15, 2025

RCKT Investor Notice: Robbins LLP Reminds Shareholders of - GlobeNewswire

Jun 15, 2025

Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead By Investing.com - Investing.com South Africa

Jun 14, 2025

Rocket Pharma’s SWOT analysis: gene therapy stock faces pivotal year ahead - Investing.com Australia

Jun 14, 2025

RCKT INVESTOR ALERT: Robbins Geller Rudman & Dowd Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Business Wire

Jun 14, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Urged to Join Class Action Before August 11, 2025Contact Levi & Korsinsky - ACCESS Newswire

Jun 13, 2025

ROSEN, A LEADING LAW FIRM, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT - TradingView

Jun 13, 2025

RCKT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire

Jun 13, 2025

Lost Money on Rocket Pharmaceuticals, Inc. (RCKT)? Contact Levi & Korsinsky Before August 11, 2025 to Join Class Action - ACCESS Newswire

Jun 13, 2025

Contact Levi & Korsinsky by August 11, 2025 Deadline to - GlobeNewswire

Jun 13, 2025

RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Business Wire

Jun 13, 2025